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Autosomal dominant polycystic kidney disease (ADPKD) leads to renal failure. The 
hallmark of ADPKD is increased epithelial proliferation, which has been proposed to 
be due to atypical signalling including abnormal JAK-STAT activity. However, the 
relative contribution of JAK-STAT family members in promoting proliferation in 
ADPKD is unknown. Here we present an siRNA JAK-STAT focused screen 
revealing a previously unknown proliferative role for multiple JAK-STAT 
components (including STAT1, STAT2, STAT4, STAT5a, STAT5b). Amongst these 
we selected to study the GH-GHR-STAT5-axis because of its known role as a 
regulator of growth in non-renal tissues. We show that STAT5 loss of function, 
facilitated by pharmacological inhibition or siRNAs, significantly reduced 
proliferation with an associated reduction in cyst growth in vitro. To study whether 
STAT5 is abnormally activated in vivo, we analyzed its expression using two 
independent mouse models of ADPKD. STAT5 was nuclear, thus activated, in renal 
epithelial cyst lining cells in both. To test whether forced activation of STAT5 can 
modulate proliferation of renal cells in vivo, irrespective of Pkd1 status, we 
overexpressed growth hormone (GH). GH mice showed increased STAT5 activity in 
renal epithelial cells, correlating with de-novo expression of cyclin D1, a STAT5 
target gene. Chromatin immunoprecipitations, revealed that STAT5 transcriptionally 
activated cyclin D1 in GH-stimulated renal epithelial but not control cells, thus 
providing a mechanism into how STAT5 enhances proliferation. Finally, we provide 
evidence of elevated GH in Pkd1nl/nl mice. Collectively, our data identify the GH-
STAT5 signalling axis as a novel therapeutic target in ADPKD.  
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INTRODUCTION 
Autosomal dominant polycystic kidney disease (ADPKD), a major cause of renal 
replacement therapy 1, frequently arises due to mutations in polycystic kidney disease 
1 (PKD1) 2. The hallmark of ADPKD is fluid-filled cysts originating from tubular 
epithelial cells 3, 4. They exhibit a hyper-proliferative and pro-apoptotic phenotype 5, 
eventually leading to end-stage renal disease. Tolvaptan, a v2-specific vasopressin 
receptor antagonist, is the first drug approved for the treatment of ADPKD, however 
additional therapeutic targets are needed because tolvaptan is not curative and side 
effects preclude treatment in some patients 6.  
 
The JAnus Kinase and Signal Transducers and Activators of Transcriptions (JAK-
STAT) is an evolutionarily-conserved pathway controlling G1-S cell cycle 
progression 7. It consists of 7 transcription factors (STAT1-5a, STAT5b and STAT6) 
and 4 tyrosine kinases (JAK1-3 and Tyk2). JAK-STAT is activated by several 
cytokines, including GH, IFNγ and OSM 8. Previous work linked abnormal Pkd1 
expression with altered JAK-STAT activity. Specifically, STAT1 interaction with the 
c-terminus of PKD1 leads to a pro-quiescent signal, thus reducing proliferation of 
renal epithelial cells 9. Antithetically, STAT6 promotes proliferation via binding to a 
cleaved c-terminal fragment of PKD1 10; moreover global knockout of STAT6 
suppresses cyst growth 11.  Accordingly, the c-terminus of PKD1 also activates 
STAT3 in ADPKD 12. Finally, inhibition of STAT3 has been associated with reduced 
cyst growth in ADPKD murine models 13, 14. However, the relative contribution of 
core components of the JAK-STAT pathway and activating cytokines in driving 
ADPKD has not been studied. To address this, we performed an unbiased screen of 
JAK-STAT pathway to determine their contribution to epithelial proliferation in 
ADPKD. Our study reveals an unexpected involvement of multiple JAK-STAT 
components. We focus subsequent studies on GH-activated STAT5 signalling, since 
this pathway has a validated function in control of tissue growth but has not been 
studied in the context of ADPKD previously.  
 
RESULTS 
GH-GHR-STAT5 axis identified as a putative pro-proliferative arm in ADPKD.  
To discover novel components of the JAK-STAT pathway that control pathogenic 
proliferation of epithelial cells in ADPKD, we performed a JAK-STAT focused RNAi 
screen of 29 genes using human renal epithelial cystic cells from a patient with 
ADPKD (OX161; 15). The siRNAs targeted core components of the JAK-STAT 
pathway, cytokines and their cognate receptors. Following siRNA treatment, the 
proliferative capacity of OX161-cells, was measured by proliferating cell nuclear 
antigen (PCNA) staining and analyzed by the one-way ANOVA test. To validate the 
screen, we demonstrated that PCNA and cyclin D1 siRNA caused a significant 
reduction in proliferation when compared to non-target RNAi treated cells (Figure 
1A). We also performed Western blotting to confirm that siRNA resulted in reduction 
of STAT protein levels (SI1). Interestingly, silencing of numerous JAK-STAT related 
genes significantly reduced proliferation of OX161 cystic cells (Figure 1B-1E). To 
investigate the interactions of identified genes and place them in functionally-related 
pathways we performed DAVID functional annotation, which identified a cluster of 6 
genes that regulate growth, namely GH, GH receptor (GHR), STAT5a, STAT5b, 
interferon gamma (IFNg) and oncostatin M (OSM). Because the GH-GHR-STAT5 
axis controls proliferation and body-growth and its involvement in ADPKD is 
currently unknown, we decided to focus the rest of our study on this.  
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Figure 1: The JAK-STAT siRNA screen 
 
 
 
 
 
 
STAT5 regulates proliferation but not apoptosis in ADPKD.  
To validate the effects of STAT5 in controlling proliferation of ADPKD-derived cells 
we employed an additional independent siRNA and a selective STAT5 small 
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molecule inhibitor (VWR-573108 16). We confirmed that VWR-573108 reduced 
phosphorylation of STAT5 without affecting STAT1/3 phosphorylation, 
demonstrating selectivity (SI Fig 1B). Using both OX161 and SKI-001 we found that 
siRNA silencing or VWR-57108 inhibitor significantly reduced proliferation (Figure 
2A and 2B). We then performed flow cytometry in cells with STAT5 siRNA or non-
target RNAi controls for the mitosis markers, histone H3 (ser10). Flow cytometry 
showed that silencing of STAT5 led a significant reduction in the marker of mitosis 
when compared to control (Fig 2C). Collectively these data suggest that STAT5 
supports proliferation in ADPKD-derived cells. To study whether STAT5 loss-of-
function affects proliferation in Pkd1 wild-type cells we used mouse Pkd1 wild-type 
epithelial cells (F1 Pkd1WT/WT) and compared their response to Pkd1-null (F1- Pkd1-/-) 
cells. We found that STAT5 silencing led to a significant reduction in proliferation in 
Pkd1 null but not wild-type cells (SI Fig 1C and CÕ). Finally, measurement of cleaved 
caspase-3 demonstrated that inhibition of STAT5 did not significantly alter the rate of 
apoptosis (Figures 2D and 2DÕ). Collectively, these data indicate that inhibition of 
STAT5 prevents proliferation without affecting apoptosis in Pkd1 mutant cells.  
 
Figure 2: STAT5 is a positive regulator of proliferation in cystic epithelial cells. 
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Nuclear STAT5 expression is increased in two independent models of ADPKD 
(Pkd1 modulation) 
To study the expression and activation of STAT5 in cells with and without deletion of 
the Pkd1 gene in vivo, we used the previously published hypomorphic Pkd1nl/nl mutant 
mouse, where Pkd1 expression is reduced to approximately 15% 17. Heterozygote 
mice were bred to obtain homozygote offspring and wild-type littermate controls, 
which survived up to the age of 10 weeks. Pkd1nl/nl mice developed progressive 
polycystic kidney disease, whereas kidneys of wild-type littermates appeared normal 
(Figure 3A). We used kidney sections from such mice to examine expression of 
STAT5 at 4 and 8 and 10 weeks of age. Immunohistochemistry revealed that STAT5 
was often expressed in cyst-lining epithelial cells in Pkd1nl/nl at all time points studied 
and its expression was strongly nuclear (Figure 3). There was a significantly higher 
percentage of nuclear STAT5 in Pkd1nl/nl mice compared to age-matched wild-type 
littermate controls at all time points (Figure 3B). We then examined the relative 
STAT5 expression during disease progression in Pkd1nl/nl mice and found that STAT5 
expression was the highest at 4 weeks of age and its expression declined by 10 weeks 
in both Pkd1 wild-type and Pkd1nl/nl (Figure 3). Coincidentally, the kidneys of 10 
week-old Pkd1nl/nl mice exhibited diffuse fibrosis consistent with previous reports 17, 
suggesting that mice at this age exhibited late-stage disease. In summary, there is a 
higher percentage of cells with ÔactiveÕ nuclear STAT5 when the Pkd1 gene is 
genetically altered, compared to wild-type control animals, suggesting that 
modulation of the Pkd1 gene activates STAT5.  
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Figure 3: STAT5 in nuclear at 4, 8 and 10 week old Pkd1nl/nl mouse kidneys. 
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Because Pkd1 is expressed in the liver and other tissues in addition to the kidneys, we 
next wished to inactivate Pkd1 specifically in kidney epithelial cells and study 
whether this can also lead to STAT5 activation. To achieve this, we deleted Pkd1 
from renal epithelial cells using the kidney specific protein (ksp) promoter driving 
Cre-ERT2, previously published 18. Thus Pkd1fl/fl; Ksp-CreERT2 mice were given 
either a 3-day administration of tamoxifen to delete Pkd1 (Pkd1del/del) or vehicle 
control (Pkd1fl/fl) and sacrificed at 11 and 16 weeks later. Analysis of multiple animals 
demonstrated that STAT5 was more strongly expressed in cyst lining cells of 
Pkd1del/del mice compared with the Pkd1fl/fl mice, which exhibited strong cytoplasmic 
STAT5 expression (compare Figure 4A with 4B). Quantification of nuclear, thus 
active, STAT5 expression indicated a statistically significant 2-fold increase in 
Pkd1del/del mice compared to Pkd1fl/fl mice, at both time points studied (Figure 4C, 11 
weeks and 4D, 16 weeks). In addition, we performed Western blotting from kidney 
lysates of control or Pkd1del/del and found pYSTAT5 in Pkd1-null kidneys at 16 weeks 
with no evidence of phosphorylation in control animals (SI Fig1D). Collectively data 
from two independent ADPKD orthologous models show that deletion of Pkd1 leads 
to increased nuclear STAT5, suggesting that Pkd1 deletion acts as an activating signal 
for STAT5. We thus reasoned that STAT5 may represent a key player in ADPKD-
pathogenesis by promoting enhanced proliferation.  
 
Figure 4: STAT5 in KSP-cre driven deletion of Pkd1 
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STAT5 antagonism reduces cyst growth in vitro 
To study whether inhibition of the STAT5 pathway plays a role in cyst growth we 
grew OX161 or F1 mouse cells on basement membrane BD matrigelTM. Cells formed 
several cysts within 24 hours which grew larger by 10 days-post-treatment (dpt) 
(Figure 5A). We found that the STAT5 inhibitor at day 1 post treatment (1dpt) and 
10dpt did not significantly alter the cyst growth, however at 6dpt there was a 
significant decrease of the cyst growth compared to DMSO vehicle control (Figure 
5B). We validated these results using an RNAi against STAT5. Similarly, to the 
pharmacological inhibitor treatment, siRNA mediated inhibition of STAT5 led to a 
significant reduction in cyst area when compared to non-target RNAi control 
transfected cells at both 6 and 10dpt (Figure 5C). To ensure that our results were not 
cell-type specific, we employed an additional 2 isogenic cell lines, with either intact 
Pkd1 (F1 mouse Pkd1+/+) or cells that the Pkd1 gene was deleted (F1 mouse Pkd1-/-). 
Inhibition of STAT5 led to a significant reduction in cyst growth in Pkd1-/- (Figure 
5E) but had no effect in Pkd1+/+ cells (Figure 5D). Taken together, these results 
corroborate that inhibition of STAT5 halts cyst growth in vitro.  
 
Figure 5: STAT5 inhibition reduces cyst growth in vitro 
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Overexpression of GH leads to high STAT5 activation and renal dilatation. 
To test directly whether activation of STAT5, independently of the Pkd1 status, in 
Pkd1 wild-type mice, can drive enhanced kidney proliferation, we used transgenic 
mice that overexpress GH under the metallothionein promoter (GHtg) 19, 20. Firstly, we 
studied the morphology of the GHtg and wild type kidneys by performing H&E 
staining. GHtg mice were previously shown to exhibit polycystic kidneys 21. We 
confirmed that the kidneys of GHtg mice exhibited multiple renal tubular dilatations 
when compared to the kidneys of wild-type mice (Figure 6A). Immunohistochemistry 
using anti-STAT5 antibodies demonstrated that STAT5 was predominantly 
cytoplasmic in wild type animals but its expression was nuclear in GHtg mice, 
suggesting that GH activated STAT5 in these kidneys (Figure 6B). Interestingly, 
nuclear STAT5 was found in dilated tubules (Figure 6B asterisk). To test whether 
ÔactivatedÕ STAT5 correlates with an increase in proliferation we stained kidneys of 
wild type and GHtg mice with cyclin D1, a well-known pro-proliferative gene shown 
here to promote cystic cell proliferation (Figure 1A). We observed higher cyclin D1 
expression in GHtg mice compared to wild type controls (Figure 6C). Rabbit IgG 
isotype control showed minimal background staining (Figure 6D). Collectively these 
data suggest that GH can drive aberrant activation of STAT5 in mouse kidney 
epithelial cells in vivo.  
Next to test whether cyclin D1 was increased in the murine ADPKD models, and to 
study whether some cells were double positive for both cyclin D1 and STAT5, we 
stained serial kidney section from Pkd1nl/nl and Pkd1del/del mice with both STAT5 and 
cyclin D1. We found cyclin D1 expression was enhanced in cyst lining cells in both 
Pkd1 models (SI Figures 2-3) and we consistently found STAT5-positive cyclin D1-
positive double positive cells (arrows). These data indicate that cyclin D1 is 
abnormally activated in these cells.  
 
Figure 6: GH enhances proliferation and activates STAT5 in vivo 
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GH-induced proliferation is mediated via the STAT5-Cyclin D1 axis. 
To investigate whether STAT5 can transcriptionally activate cyclin D1 in renal 
epithelial cells, we used transformed human derived Pkd1 wild-type tubular epithelial 
cells (UCL93) 15, where activation of STAT5 can be temporally controlled by 
exogenous recombinant GH. Stimulation of cells with GH led to a marked increase in 
nuclear STAT5 compared with vehicle-treated cells (Figure 7A). We performed 
chromatin immunoprecipitation (ChIP) experiments using anti-STAT5 antibodies to 
study the binding of STAT5 to the CCDN1 promoter. ChIPs revealed that stimulation 
with GH significantly increased association of STAT5 with the cyclin D1 promoter 
compared to vehicle-treated controls (Figure 7B). By contrast binding of histone H3 
to the RPL30 gene (a positive control for the ChIP technique) was similar in vehicle- 
and GH-treated cells (Figure 7B). To test whether GH-induced proliferation can be 
reversed by silencing of cyclin D1, we use a specific siRNA against CCDN1 and 
found that silencing of cyclin D1 led to reduced proliferation (Figure7C). Collectively 
our data suggest that GH activated STAT5 enhances proliferation via cyclin D1 in 
normal renal epithelial cells; whether GH signalling is enhanced in human and murine 
models of ADPKD is currently unknown.  
 
Figure 7: GH enhances proliferation in a STAT5 dependent manner. 
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Serum GH is elevated in Pkd1nl/nl mice. 
We next wished to study whether GH is abnormally expressed in murine ADPKD. 
Firstly, we investigated whether renal tubular epithelial cells express the GH-receptor 
(GHR), which is required to sense and respond to GH. To do this we stained sections 
of kidneys from multiple animals with an anti-GHR antibody and performed confocal 
microscopy. We found that both wild-type and Pkd1nl/nl animals express GHR in 
epithelial cells (Figure 8A). We also noted that GHR staining is punctate, consistent 
with ÔactivatedÕ internalized receptor. GH is made by the pituitary gland and is found 
in serum, therefore, to study whether inactivation of Pkd1 leads to elevated GH we 
collected serum from multiple animals at two different time-points, 5 and 10 weeks of 
age (representing early and late disease) from Pkd1nl/nl and corresponding wild-type 
controls. Flow-cytometry bead-based ELISAs were performed to measure levels of 
GH, and we found that Pkd1nl/nl animals have consistently higher circulating GH when 
compared to wild-type controls at both time-points studied (Figure 8B&C). 
Collectively, these data suggest that GH-initiated signalling is significantly more 
active in Pkd1nl/nl when compared to control, thus suggesting that GH may be 
underlying the atypical activation of STAT5 in murine ADPKD. Tissue-specific 
deletion of the GH gene is required to study the involvement of GH in driving 
ADPKD.  
 
Figure 8: GH signalling in murine ADPKD 
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DISCUSSION 
 
Mouse knockout studies have elucidated a clear role for STAT5 as a positive 
regulator of proliferation in epithelial non-renal tissues 22-24; making STAT5 an 
attractive target to study in ADPKD. We report that STAT5 contributes to the 
pathogenesis of ADPKD by showing that (i) STAT5 is expressed in cyst-lining 
epithelial cells in two independent murine models of ADPKD, (ii) STAT5 controls 
proliferation of ADPKD-derived human epithelial cells (iii) inhibition of STAT5 
results in reduced cyst growth in vitro (iv) GH activates STAT5 transcription leading 
to enhanced proliferation and (v) serum GH is elevated in the Pkd1nl/nl mouse. 
However, whether GH is elevated in human ADPKD remains unknown.   
 
STAT5 knockout mouse studies have not reported any renal abnormalities making 
STAT5 a potential therapeutic target since it is not required for normal kidney 
function 22-24. One strategy to inhibit STAT5 is via the use of JAK kinase inhibitors, 
which prevent STAT5 phosphorylation. The benefits of using JAK inhibitors include 
the subtype-selective inhibition of these enzymes and the fact that they are already 
approved to use in malignancies and rheumatoid arthritis 25-29. To overcome toxicity, 
which can arise with some JAK inhibitors, a more targeted approach can be 
employed. For instance, targeting the SH2-domain of specific STATs could 
demonstrate selectivity with reduced side-effects. Here we used a selective small 
molecule STAT5 SH2-domain inhibitor that inhibits transcriptional output by 
blocking the interactions between STAT5 and SH2 domains, without affecting 
STAT3 or STAT1 30. Additional SH2 binders that selectively inhibit STAT5 at much 
lower concentrations have been generated 31. Future animal studies are needed to 
compare the efficacy of the different STAT5 SH2 compounds in reducing cyst growth 
in ADPKD models. Alternatively, HDAC6 inhibition was recently shown to be 
effective in reducing cyst growth in murine PKD 32; this is particularly relevant to this 
study because HDAC inhibition reduces STAT5 transcriptional activity 33, therefore 
use of selective HDAC inhibitors can be employed as an alternative strategy to inhibit 
atypical STAT5-initiated signalling.  
 
Interestingly, STAT6, a known positive regulator of proliferation 34, is aberrantly 
activated in cyst-lining cells and its inhibition leads to reduced proliferation 
associated with a better outcome in murine ADPKD 10, 11. In addition, a number of 
studies have demonstrated a pro-proliferative role for STAT3 in ADPKD (reviewed in 
35). Thus, we were surprised to find that neither STAT3 nor STAT6 silencing reduced 
proliferation of human ADPKD-derived epithelial cells; thus we conclude that our 
screen might underestimate the contribution of some JAK-STAT components. This 
could be explained by differences in the models used (murine ADPKD versus human 
ADPKD-derived cells). Alternatively, both STAT3/6 are known immune regulators 
and therefore may mediate their effects partly via acting on immune cells. Tissue-
specific deletion of STATs is required in order to evaluate the contribution of the 
JAK-STAT pathway in molecular and genetic detail. Collectively, these findings 
highlight the complexity of the JAK-STAT pathway and the importance of using 
complementary cell culture and mouse models to study ADPKD. 
 
Previously GHtg mice were shown to exhibit a shorten life-span 36, chronic 
inflammation, increased cancer rates 37 and a profound cystic kidney phenotype 
already at a young age 21, 38. Because GH is a potent activator of STAT5 39-41 we used 
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GHtg mice to study the effects of STAT5 activation in renal epithelial cells. Our work 
verifies the renal tubular dilatations, previously reported in GH-transgenic mice, and 
also demonstrates that STAT5 and Cyclin D1 are both activated in dilated tubules, 
suggesting that they contribute to tubular dilatation. Because GHtg mice do not 
represent an ADPKD model, we then studied whether GH is elevated in an ADPKD 
mouse model. We show that circulating GH is elevated in serum of mice with 
ADPKD when compared to wild-type. This finding is important in relation to the 
ALADIN clinical trials; where use of the long-lasting somatostatin analogue 
octreotide, reduced mean total kidney volume at 1 year follow-up 42. Interestingly, 
administration of octreotide has been shown to reduce circulating GH 43. Thus, one 
alternative mechanism to explain the effects of octreotide is via inhibition of 
circulating GH and suppression of signalling triggered by STAT5.  
 
Here we describe the first report of aberrantly-activated STAT5 expression in both 
human cystic cell lines and mouse models of ADPKD and show that mechanistically 
STAT5 drives proliferation partly via transcriptionally activating cyclin D1. The 
abnormal activation of STAT5 in ADPKD could be explained by a number of 
possible mechanisms, in addition to the effects of elevated serum GH. STAT3 and 
STAT6 become aberrantly activated by binding to a cleaved c-terminal fragment of 
Pkd1 35. Therefore, potentially STAT5 activity may be enhanced via binding to Pkd1. 
However, tissue specific Pkd1 knockout also leads to enhanced STAT5 activity, thus 
at least in mouse models, STAT5 does not physically interact with Pkd1. An 
alternative hypothesis is that inactivation of Pkd1 genetically interacts with STAT5 
via altering the balance of pro- and anti-proliferative signals. Indeed, Pkd1 was shown 
to activate STAT1 transcription leading to an anti-proliferative and pro-quiescent 
phenotype in renal epithelial cells 9, this is consistent with the role of STAT1 as a 
strong anti-proliferative gene in cancer 44. Thus, we hypothesize that in the absence of 
Pkd1, or when Pkd1 expression is lowered, the anti-proliferative Pkd1-induced 
STAT1 pathway is inactivated (or its activity reduced) thus shifting the balance 
towards more proliferation via enhanced STAT5 activation.  
 
In conclusion, we present the first data that identifies the growth-hormone-STAT5-
Cyclin D1 axis as abnormally activated in ADPKD, leading to enhanced proliferation. 
Future studies are needed to selectively inhibit STAT5 in the kidney in order to test its 
putative pathogenic role in ADPKD. 
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METHODS  
Animals. We used 40-day old iKSPCreERT2/ Pkd1fl/fl mice, treated with tamoxifen 
(5mg) or vehicle for three consecutive days 18. Mice were sacrificed at 11 or 16 weeks 
post-tamoxifen treatment. GH transgenics, where GH is driven by the metallothionein 
promoter were used 21. Pkd1nl/nl, harboring an intronic neomycin-selectable marker, or 
wild type littermate controls were used 45. Pkd1nl/nl or control mice were sacrificed at 
4-10 weeks of age and kidneys collected. Serum and kidney GH was measured using 
an ELISA (MPTMAG-49K, Millipore). All animal experiments were performed 
under the authority of a UK Home Office license.  
 
Cell lines. Conditionally-immortalized Pkd1 wild-type (UCL93) and ADPKD-
derived lines (OX161 and SKI-001)15 are tubular epithelial cells isolated from human 
kidneys and immortalized by transduction at an early passage (P1-4) with a retroviral 
vector containing a temperature-sensitive large T antigen and the catalytic subunit of 
human telomerase 46. The F1-WT renal epithelial cells were previously isolated from 
kidney papillae of the Pkd1fl/fl mouse (B6.129S4-Pkd1tm2Ggg/J; the Jackson 
Laboratory). They were immortalized with the lentiviral vector VVPW/mTert 
expressing the mTert. To delete Pkd1 and produce F1/Pkd1-/- cells they were 
subsequently transfected with VIRHD/HY/Silntβ1/2363 lentivectors. Positive 
populations were selected by hydromycin selection 47. Normal renal epithelial HKC-5 
cells were previously isolated from a human nephrectomy specimen 48.  
 
Protein biochemistry, ChIPs and antibodies. Cells were lysed using ice-cold Lysis 
Buffer (50mM Tris (pH 7.4) 250mM NaCl, 0.3% Triton X-100, 1mM EDTA) 
supplemented with protease inhibitor cocktail (Roche), freeze-thawed and sonicated. 
Whole cell lysates were boiled in 2xLaemmeli sample buffer for 5 minutes. Samples 
were resolved by SDS-PAGE and transferred using the Mini-PROTEAN system (Bio-
Rad). Primary antibodies were anti-b-actin (ab8226, Abcam), anti-phosphorylated 
STAT5 (p-STAT5) (4322, Cell Signalling), anti-STAT5 (HPA027873, Sigma). 
Chromatin IPs were performed using SimpleChIP enzymatic chromatin IP kit with 
magnetic beads (9003, cell signalling), following manufacturerÕs instructions.  
 
Immunofluorescence. Cells grown on coverslips were fixed in ice-cold methanol 
prior to blocking in 2% milk in TBST for 30 minutes and incubated with primary 
antibodies overnight at 4oC. Antibodies used were: PCNA (2586, Cell Signalling 
(1:400), STAT5 (HPA027873, sigma (1:200)). Cells were washed and incubated with 
secondary anti-mouse AF488 (A-11001, Invitrogen (1:250) and anti-rabbit AF594 (A-
11037, Invitrogen (1:250) antibodies. Microscopy was carried out using a confocal 
microscope. Quantification of fluorescence intensity was done by splitting the RGB 
image into individual channels, measuring mean grey value and calculating optical 
density using the formula OD=log (max intensity / mean intensity).  
 
JAK-STAT inhibitors. VWR-573108 is a previously described STAT5 chromone-
based inhibitor 16, also known as NÕ-(4-oxo-4H-chromen-3-yl)methylene) 
nicotinohydrazide was purchased from VWR (573108) and used at a final 
concentration of 100 μM. Cells were treated with equal volumes of DMSO as a 
vehicle control.  
 
RNAi screen and transfections. 29 different RNAi smartpools from Dharmacon 
were used to reverse transfect the cystic cell line OX161 at a final concentration of 15 
nM of RNAi using RNAiMAX reagent (Invitrogen) using manufacturerÕs 
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instructions. For individual line transfections, cells were reverse transfected with 
20nM of Dharmacon gene specific RNAi using RNAi MAX transfection reagent 
(Invitrogen) following manufacturerÕs instructions.  
 
Statistical analysis. All data were analysed with Prism Graphpad and Non-
parametric, two-tailed, either Mann-Whitney T-tests or one-way ANOVA were 
performed and results with a P value of 0.05 or lower were considered significant.  
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FIGURE LEGENDS 
Figure 1 
JAK-STAT subset RNAi screen.  
A. Cystic human tubular epithelial cells (OX161) were transfected in triplicate with 
one of the 29 RNAi sequences for 72 hours. Cells were then fixed and stained with 
PCNA and analysis of proliferation (PCNA) was performed by microscopy and 
scoring with Image J. B. Proliferation quantification of transcription factors, C. 
kinases, D receptors and E cytokines are shown. Silencing of core JAK-STAT 
components caused a significant change in proliferation of cystic tubular epithelial 
cells. Significant differences are shown with exact P values (** indicate P values of 
less than 0.0072 and * P values less than 0.05).  
 
Figure 2 
Proliferation is inhibited in cystic by inhibition of STAT5.  
A. ADPKD-derived human epithelial cells, OX161 or SKI-001, were reversed 
transfected with either STAT5 or non-target siRNA and incubated for 72 hours (n=3). 
Cells were then fixed and stained with PCNA primary antibody and visualized using 
fluorescent microscopy using an anti-mouse cy3 secondary antibody (red), nuclei 
were counterstained with DAPI (blue). Analysis of data from three independent 
experiments is shown with P values indicated. B. STAT5 inhibitor (100μM) or 
DMSO were added to OX161 or SKI-001cells and 48 hours later cells were fixed and 
DAPI positive nuclei were counted to study cell numbers. Analysis of data from three 
independent experiments is shown with P values indicated. C. Flow cytometry for 
histone H3 (ser10) was carried out to determine whether silencing of STAT5 reduced 
mitosis when compared to non-target RNAi treated cells in two cell lines (OX161, left 
and SKI-001, right). D. OX161 cells were treated with 100μM of STAT5 inhibitor or 
equivalent volume of DMSO (1μL) for 48 hours. They were stained with cleaved 
caspase 3 (red) and nuclei were counterstained with DAPI (blue), representative 
pictures are shown. DÕ. Quantification of PCNA staining normalized for area of cells 
is shown. Analysis of data from three independent experiments is shown with P 
values indicated. 
 
Figure 3 
STAT5 expression in Pkd1nl/nl mice at 4, 8 and 10 weeks of age. 
A. Representative images of kidneys sections stained with STAT5 (top panel, 
greyscale; lower panel, red) or isotype IgG control from 4 and 8 and 10-week old WT 
mice (top) and 4, 8 and 10-week old PKD1nl/nl mice (bottom). Nuclei were 
counterstained blue with TOPRO. Confocal microscopy was carried out at 63x 
magnification. B. Quantification of nuclear STAT5 in 4, 8 and 10 weeks old mice 
(n=4 mice in each group). Statistical analysis was performed using an unpaired one-
way ANOVA. 
 
Figure 4 
STAT5 is nuclear in kidneys at both 11 and 16-week post deletion of murine 
Pkd1.  
A. Predominantly cytoplasmic STAT5 staining was observed in Pkd1 intact control 
kidney tissues stained with a STAT5 antibody (top panel, greyscale; lower panel, red) 
and counterstained with TOPRO (blue) at both 11 and 16 weeks of age. Control 
isotype IgG staining was also performed. Representative pictures are shown. B. 
Nuclear STAT5 with some cytoplasmic staining was observed in ADPKD kidney 
sections stained with STAT5 antibody (top panel, greyscale; lower panel, red) in mice 
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with tamoxifen induced Pkd1 inactivation at both 11 (n=5) and 16 weeks (n=5) of 
age. Control isotype IgG staining was also performed. Representative pictures are 
shown. C. Quantification of cells exhibiting nuclear STAT5 at 11 weeks and D. at 16 
weeks is shown. To quantify image was split and threshold applied, using Image J, to 
count total number of nuclei then cells positive for nuclear STAT5 were counted 
manually, percentage of nuclear cells was calculated by dividing number of positive 
cells by total number of cells.  
 
Figure 5 
STAT5 inhibition reduces cyst growth in vitro. 
A. Representative images of OX161, PKD1 mutant cells, grown in BD-matrigel at 
day 1 (left panel) and day 10 (right panel). B. Inhibition of STAT5 with the use of 
100μM of STAT5 inhibitor led to a significant reduction in cyst growth as measured 
at both 6-days post treatment (dpt), when compared to DMSO vehicle control; n=5. 
C. Inhibition of STAT5 using specific siRNAs also led to a significant reduction in 
cyst growth when compared to non-target RNAi control (NT RNAi), n=5. D. 
Inhibition of STAT5 with the use of the inhibitor at days 1, 6 and 10dpt in F1 
Pkd1+/+ mouse cell line or E. the isogenic F1 Pkd1-/- line. One-way ANOVA test 
was used for statistical analysis. 
 
Figure 6 
GH enhances proliferation and activates STAT5 in vivo. 
A. Representative pictures of hematoxylin and eosin staining are shown for WT 
kidneys (n=7) and GHtg kidneys (n=8). G denotes the glomeruli, * indicates tubular 
dilatation and V, vessels. B. STAT5 immunohistochemistry was performed in both 
the WT and GHtg mice and representative pictures are shown. Arrows point at strong 
STAT5 nuclear expression in dilated tubules. C. Immunohistochemistry for cyclin D1 
was performed in WT and GHtg mice and isotype control staining is shown in D.  
 
Figure 7  
GH enhances proliferation in a STAT5 dependent manner. 
A. PKD1 WT cells (UCL93) were treated with GH or vehicle control and stained with 
an anti-STAT5 antibody (red), nuclei were counterstained with DAPI (blue). Staining 
was analysed using a fluorescent microscope. B. ChIPs were performed for STAT5 or 
histone 3 (positive control, right panel) and quantitative PCR of the antibody 
associated chromatin was performed. Melting curves of the two primer sets (CCDN1 
for STAT5 and PRL30 for histone H3) are shown in the middle panel. Data are 
expressed as fold enhancement over IgG. C. Cells were either transfected with a non-
target RNAi or a CCDN1 specific siRNA and either treated with vehicle 
 or GH, followed by staining with PCNA (red) and nuclei were counterstained with 
DAPI (blue).  
 
Figure 8 
Pkd1nl/nl exhibit elevated serum GH. 
A. GHR staining in kidney section of WT mice (n=4) or mice with Pkd1 deletion, 
Pkd1nl/nl (n=4) was performed with anti-GHR antibodies and representative images 
are shown alongside isotype IgG contol. Anti-GHR is in greyscale/red, nuclei 
counterstain with TOPRO (blue), confocal images are shown at 63x magnification. 
B & C. Serum GH was measured in animals with intact Pkd1 (WT) or Pkd1nl/nl using a 
magnetic bead-based ELISA. Three animals per group were tested at 5 weeks of age 
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(B) and four animals per group at 10 weeks of age (C). ELISA results were subjected 
to student t-tests with any values lower than 0.05 considered significant.  
 
Supplementary Figure 1. 
A. Verification of silencing of STAT1, STAT3 and STAT5 was performed by 
Western blotting and amount of each protein was compared to that of non-target 
RNAi. b-actin acted as an internal loading control. B. Western blot was performed for 
pYSTAT5, total STAT5, pYSTAT3, total STAT3, pYSTAT1 and total STAT1 as 
well as β-actin which acted as a loading control. Human cells were treated either with 
IFN-α alone, to trigger JAK-STAT signalling, or IFN-α and STAT5 inhibitor 
simultaneously. These data illustrate that the STAT5 inhibitor blocks canonical 
pYSTAT5, without affecting total STAT5 and without affecting STAT1 and STAT3 
phosphorylation. C. Flow cytometry was performed in Pkd1 WT and Pkd1-/- cells 
stained with an anti-P(ser10) histone H3 mitotic marker antibody, a representative 
flow chart for Pkd1-/- is shown. CÕ. Quantification of percentage of mitotic cells in 
both WT and F1 Pkd1-/- cells was carried out, there was no statistical difference in the 
WT cells but there was a statistically significant decline in % of mitotic cells in F1 
Pkd1-/- cells. D. Western blot was performed using whole kidney lysates from WT and 
11 or 16 weeks old mice after deletion of Pkd1. Blotting of membrane with 
phopshotyrosine STAT5 (pY STAT5) revealed a doublet, which corresponds to 
pYSTAT5a/b in Pkd1 KO mice at 16 weeks of age. PCNA also revealed enhanced 
proliferation in Pkd1 KO mice when compared to WT controls. b-actin was studied as 
an internal loading control. 
 
Supplementary Figure 2. 
A and B. Kidneys of Pkd1nl/nl mice at 6 (n=4) and 8 (n=4) weeks of age were stained 
with cyclin D1 (left panel) and STAT5 (right panel), and representative images of 
serial sections are shown with arrows pointing at cells exhibiting staining for both 
cyclin D1 and STAT5.  
 
Supplementary Figure 3. 
Serial section of the Pkd1 KO mice at 11 weeks of age (n=5) were stained either with 
cyclin D1 (left) or STAT5 (right). Representative images are shown with arrows 
pointing to cells that express both cyclin D1 and STAT5.  
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